9.4 Prescription Labeling, Poison Prevention Packaging (PPPA) & USP Standards

9.4 Prescription Labeling, Poison Prevention Packaging (PPPA) & USP Standards

The final physical and informational artifact dispensed by a pharmacy is the prescription container, its affixed label, and its packaging enclosure. Both federal and state laws impose strict labeling standards to prevent medication errors, avoid drug misbranding under the Food, Drug, and Cosmetic Act (FDCA § 503(b)(2)), and protect young children from accidental poisoning under the Poison Prevention Packaging Act of 1970 (PPPA; 16 CFR Part 1700).

In Oklahoma, prescription labeling is governed primarily by Title 59 O.S. § 353.20 and the Oklahoma Administrative Code (OAC 535:10-9-1), with packaging stability and beyond-use dating guided by United States Pharmacopeia (USP) general compendial chapters.

---

Oklahoma Prescription Labeling Requirements: Title 59 O.S. § 353.20 & OAC 535:10-9-1

Every prescription container dispensed to an outpatient in Oklahoma must bear a firmly affixed label containing specific statutory and regulatory elements. Omission of any required element renders the dispensed drug misbranded under law.

+-------------------------------------------------------------------------+
|             MANDATORY OKLAHOMA PRESCRIPTION LABEL ELEMENTS              |
+-------------------------------------------------------------------------+
| 1. Pharmacy Identifier: Name, Physical Address, and Phone Number        |
| 2. Prescription Number: Unique serial number assigned to prescription   |
| 3. Date of Dispensing: Date prescription filled or refilled             |
| 4. Patient Name: Full name of the patient (or animal owner & species)   |
| 5. Prescriber Name: Name of the licensed prescribing practitioner       |
| 6. Drug Details: Trade name or established generic name, strength, qty  |
| 7. Generic Substitution: Generic name + manufacturer + brand prescribed |
| 8. Directions for Use: Clear, specific patient administration directions|
| 9. Beyond-Use Date (BUD): Expiration date or BUD (max 1 year / mfr date)|
| 10. Auxiliary Statements: Necessary cautionary / storage warnings       |
| 11. Federal CDS Warning: Schedules II, III, IV transfer prohibition    |
+-------------------------------------------------------------------------+

Detailed Breakdown of Mandatory Label Elements

1. Pharmacy Identification: The legal trade name, full physical street address, and active telephone number of the dispensing pharmacy.
2. Serial Prescription Number: The unique sequential prescription number (Rx #) assigned to the order in the pharmacy's dispensing database.
3. Date of Dispensing: The exact date on which the prescription was initially prepared and filled, or the date of the most recent refill.
4. Patient Identification:
   • For human patients: The full first and last name of the patient.
   • For veterinary patients: The last name of the owner, the owner's first name, the animal's name/identification, and the species of the animal (e.g., "Smith, John (Canine: Max)").
5. Prescriber Name: The full name of the prescribing practitioner (e.g., "Dr. Sarah Jenkins, MD").
6. Drug Name, Strength & Quantity: The established proprietary (brand) name or generic chemical name, the dosage strength (e.g., "20 mg"), dosage form (e.g., "Tablet"), and the exact physical quantity dispensed.
7. Generic Substitution Disclosure: When a generic substitution is executed under Title 59 O.S. § 353.21, the label must state the generic name, the name of the manufacturer or distributor, and the brand name prescribed (e.g., "Simvastatin 20 mg Tablet — Generic for Zocor — Mfd by: Sandoz").
8. Directions for Use: Clear, specific administration instructions provided by the practitioner. Vague instructions like "Use as directed" are legally impermissible unless specifically justified by specialized dosing schedules (such as tapering dosepacks).
9. Beyond-Use Date (BUD): The beyond-use date or expiration date assigned by the pharmacist, which cannot exceed the manufacturer's expiration date on the stock bottle or one year from the date of dispensing, whichever is earlier.
10. Cautionary and Auxiliary Statements: Appropriate cautionary labels (e.g., "Take with food", "Do not drink alcoholic beverages", "Finish all medication unless directed otherwise", "May cause drowsiness").

The Federal CDS Transfer Warning (21 CFR § 290.5)

For all Schedule II, Schedule III, and Schedule IV controlled dangerous substances dispensed to a patient, federal and Oklahoma law mandate that the following exact cautionary statement be printed prominently on the prescription label or container:

"CAUTION: Federal law prohibits the transfer of this drug to any person other than the patient for whom it was prescribed."

(Note: Under federal CSA regulations, this transfer warning is legally required for Schedules II, III, and IV; Schedule V drugs are technically exempt under federal rule, though Oklahoma and standard practice routinely print this warning across all controlled substances).

---

The Poison Prevention Packaging Act of 1970 (PPPA)

The Poison Prevention Packaging Act (PPPA), codified in 15 U.S.C. §§ 1471–1477 and enforced by the Consumer Product Safety Commission (CPSC) under 16 CFR Part 1700, was enacted to protect children under five years of age from accidental poisoning and death resulting from opening and ingesting toxic household substances and prescription drugs.

Child-Resistant (C-R) Packaging Standards

A package is legally defined as child-resistant if:

• At least 80% of children under 5 years of age cannot open the packaging during a 10-minute testing period (5 minutes of testing without demonstration, followed by 5 minutes with a visual demonstration), and
• At least 90% of adults aged 50 to 70 years can open and close the child-resistant package within a 5-minute initial period and a 1-minute subsequent screening.

                  PPPA WAIVER RULES: PATIENT vs. PRESCRIBER
+-------------------------------------------------------------------------+
| PATIENT / PURCHASER WAIVER:                                             |
|   - Authority: Full authority to request non-child-resistant packaging  |
|   - Scope: May request a BLANKET WAIVER for all present & future Rxs    |
|   - Format: May be oral or written (signed written waiver recommended)  |
|   - Verification: Periodic confirmation is best practice                |
+-------------------------------------------------------------------------+
| PRESCRIBING PRACTITIONER WAIVER:                                        |
|   - Authority: May request non-child-resistant packaging for patient    |
|   - Scope: ONLY on a PER-PRESCRIPTION basis (single Rx & its refills)   |
|   - Prohibition: CANNOT issue a blanket waiver for all of a patient's   |
|     prescriptions across different orders                               |
+-------------------------------------------------------------------------+

The Legal Framework for PPPA Waivers

Under 16 CFR § 1700, prescription drugs subject to PPPA regulations must be dispensed in child-resistant packaging unless an exemption or waiver applies:

1. Patient Blanket Waiver: A patient (or the patient's legal representative) may request that all of their medications be dispensed in non-child-resistant (easy-open) containers. The patient may execute a single blanket waiver covering all present and future prescriptions. While federal law permits this request to be made orally, Oklahoma pharmacies should obtain a signed, written blanket waiver document and periodically re-confirm the patient's preference.
2. Prescriber Per-Prescription Waiver: A prescriber may request that a prescription be dispensed in a non-child-resistant container (for example, for an elderly patient with severe rheumatoid arthritis). However, the prescriber CANNOT issue a blanket waiver for all prescriptions written for that patient. The prescriber's waiver applies only to the single prescription order (and any refills authorized under that specific order).

Reuse of Prescription Containers & Safety Closures

Under PPPA safety rules:

• Plastic Vials and Plastic Caps: When refilling a prescription, a pharmacist CANNOT reuse plastic prescription vials or plastic safety caps. Plastic containers wear and deform over time, compromising the child-resistant locking mechanism.
• Glass Containers: Glass prescription bottles may be reused upon refilling ONLY if a brand-new plastic safety closure/cap is installed. The glass body does not wear, but the plastic cap mechanism must be replaced.

---

Statutory PPPA Exemptions (Exempt Drug Categories)

Congress and the CPSC established specific statutory exemptions from child-resistant packaging requirements for medications where rapid emergency access is critical or where the formulation/packaging presents minimal pediatric toxicity risk:

---

United States Pharmacopeia (USP) Standards & Beyond-Use Dating (BUD)

Every pharmacist must understand the critical legal and physical distinction between a Manufacturer Expiration Date and a Dispensing Beyond-Use Date (BUD):

+-------------------------------------------------------------------------+
|        MANUFACTURER EXPIRATION DATE vs. DISPENSING BEYOND-USE DATE      |
+-------------------------------------------------------------------------+
| Manufacturer Expiration Date:                                           |
|   - Determined by rigorous manufacturer stability testing under cGMP    |
|   - Applies to unopened, original, sealed commercial packaging          |
|   - Stamped on commercial bulk bottles (e.g., "EXP 11/2028")            |
+-------------------------------------------------------------------------+
| Dispensing Beyond-Use Date (BUD):                                       |
|   - Assigned by the pharmacist when drug is repackaged or dispensed     |
|   - Accounts for exposure to light, moisture, oxygen, and container     |
|   - Governed by USP Compendial Standards (<659> and <7>)                |
|   - Standard Rule for Multiple-Unit Vials: Shorter of 1 year or Mfr Exp |
+-------------------------------------------------------------------------+

USP Standards for Non-Sterile Solid and Liquid Repackaging

Under USP <659> Packaging and Storage Requirements and USP <7> Labeling, when non-sterile solid oral dosage forms (tablets, capsules) or liquid oral dosage forms are repackaged from a manufacturer's commercial bulk bottle into a standard multiple-unit prescription container (e.g., amber plastic vial):

$\text{Prescription BUD} = \min(\text{Manufacturer Expiration Date}, \text{Date of Dispensing} + 1 \text{ Year})$

• The One-Year Rule: The beyond-use date cannot exceed one (1) year (12 months) from the date the drug is dispensed or repackaged, or the manufacturer's stated expiration date, whichever is shorter.
• Month-Only Expiration Interpretation: If a manufacturer bottle states an expiration date formatted as a month and year only (e.g., "EXP 08/2027"), federal and USP compendial standards interpret the expiration date as the last day of that month (August 31, 2027).

Unit-Dose Repackaging Standards (Single-Unit Containers)

When a pharmacy repackages bulk solid oral dosage forms into individual unit-dose blister packages for institutional use, USP guidelines specify that the assigned BUD must not exceed:

• Six (6) months (or 1 year under certain USP revisions) from the date of repackaging, or
• 25% of the remaining time between the date of repackaging and the manufacturer's original expiration date, whichever is shorter.